Corporate Information

• 25 Jan, 2022
  Signifikant minskad tumörtillväxt med Tumorad® enligt nya prekliniska resultat
• 13 Jan, 2022
  Spago Nanomedicals phase 1 study with SpagoPix shows clear contrast enhancement and is expanded into new indications
• 13 Jan, 2022
  Spago Nanomedicals fas 1-studie med SpagoPix visar tydlig kontrast och utökas till nya indikationer
• 6 Dec, 2021
  Tumorad® shows good safety in preclinical studies
• 6 Dec, 2021
  Tumorad® visar god säkerhet i prekliniska studier
• 2 Dec, 2021
  Second dose group fully recruited in Spago Nanomedical’s phase 1 study with SpagoPix
• 2 Dec, 2021
  Andra dosgruppen färdigrekyterad i Spago Nanomedicals fas 1-studie med SpagoPix
• 10 Nov, 2021
  Spago Nanomedical selects Cmed as its CRO for the first clinical trial with Tumorad®
• 10 Nov, 2021
  Spago Nanomedical anlitar Cmed som CRO för den första kliniska studien med Tumorad®
• 21 Oct, 2021
  Nomination committee appointed for the 2022 Annual General Meeting in Spago Nanomedical